Pipeline Overview

Isarna has established a broad portfolio of next-generation first- and best-in-class antisense oligonucleotides blocking three key TGF-β variants with therapeutic potential across a range of indications.

In ophthalmological indications, our compounds are clearly differentiated from the currently marketed anti-VEGF compounds such as Eylea and Lucentis and offer the potential for improved efficacy. Isarna is about to initiate Phase 2a development in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). The approach has near-term upside potential through expanding the program into other key ophthalmology indications i.e., dry forms of age-related macular degeneration.

 

 

Current Pipeline Status